# Disparities in the consensus for treatment of chemotherapy-induced thrombocytopenia

## TL;DR

This study explores how doctors in Armenia manage chemotherapy-induced low platelet counts, revealing significant differences in their treatment approaches.

## Contribution

The paper presents the first survey on chemotherapy-induced thrombocytopenia management in Armenia, highlighting knowledge gaps and practice variations.

## Key findings

- Physicians in Armenia use varying platelet thresholds to define thrombocytopenia.
- All physicians use platelet transfusions prophylactically, not only for active bleeding.
- Only 53% of respondents reported 24/7 access to platelet products.

## Abstract

Chemotherapy-induced thrombocytopenia (CIT) is an arduous complication of chemotherapy to be dealt with, and there are many unmet needs in this field to be addressed on the global front. We have conducted this study to contribute to the understanding of existing knowledge gaps of CIT management and highlight the direction to focus future investigations.

This was an academic single-institution report on a cross-sectional study evaluating CIT management practices using platelet (PLT) transfusions by haematologists and oncologists in Armenia.

Physicians’ opinions differed significantly when it came to defining thrombocytopenia by PLT levels. 13.2% of those surveyed considered thrombocytopenia to be when PLT counts fall below 180 × 109/L, 42.1% defined thrombocytopenia to have a PLT threshold of 150 × 109/L, 15.8% and 21.0% specialists setting their thresholds at 140 × 109/L and 100 × 109/L, respectively.

All physicians managed CIT by performing PLT transfusions for prophylactic purposes (i.e., when PLT count falls below a certain threshold) with none of them transfusing PLTs only on-demand to address active bleeding. 73.3% haematologists (adult), 57.1% medical oncologists, and 50% paediatricians deemed 10 × 109/L as the threshold PLT count for transfusing afebrile patients with haematologic malignancies (besides acute promyelocytic leukaemia (APL)) and solid tumours.

PLT products availability varied among the respondents, with only 53% of them responding that they had 24/7 access.

CIT is a complication of interest to physicians worldwide and has not been resolved yet. This is the first conducted survey regarding CIT and the initial step for further research.